Program
ebnk-1822h2 dual-target cldn18.2
A development code. Also written as “EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)” and “EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells”.
Its studies are mostly in Neoplasm Metastasis, led by Beijing Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotech | 33 open or running | phase 2since Mar 14, 2026 | Mar 14, 2026 | Feb 14, 2027phase 2 · NCT07480928 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2026First study: phase 2 study in Neoplasm MetastasisFirst studyNCT07480928 · 42 planned · China
- May 25, 20262 phase 2 studiesNCT07622940, NCT07627711
Ahead
- Feb 14, 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT07480928
- Mar 14, 2027Primary completion: phase 2 study in RecurrenceNCT07622940
- Apr 14, 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT07627711
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07627711Neoplasm Metastasis · China | 2 | Recruiting | Apr 14, 2027 | 42 |
| NCT07622940Recurrence · China | 2 | Recruiting | Mar 14, 2027 | 36 |
| NCT07480928Neoplasm Metastasis · China | 2 | Recruiting | Feb 14, 2027 | 42 |
How it is read
Names in the registry
- “EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)”, 2 entries
- “EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells”, 1 entry
Codes read as this program: CLDN18.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.